News
Spark Therapeutics is riding a double shot of positive news about its gene therapy treatment for RPE65-mediated inherited retinal disorders that’s given its stock a…
Read MoreWith another failed trial of its glaucoma candidate trabodenoson in hand, Inotek Pharmaceuticals Corp. is pondering options that could include selling the company, but finding…
Read MoreAs Applied Genetic Technologies Corporation (AGTC) heads into the summer with encouraging results for two of its lead candidates using the adeno-associated virus-based gene technology…
Read MoreNovartis Reports Positive Phase III Results for RTH258 Novartis reported that RTH258 (brolucizumab) 6 mg met the primary and key secondary endpoints of non-inferiority compared…
Read MoreWe see ophthalmology as one of the more innovative specialties in healthcare, but does that excitement translate to the public markets? In October, we launched…
Read MoreWhen Novartis last week announced positive outcomes from two Phase III trials for new age-related macular degeneration (AMD) drug brolucizumab (RTH258), it seemed the other…
Read MoreNow that the Implandata Ophthalmic Products has received approval to commercialize its implantable glaucoma-monitoring device in the European Union, it’s setting its sights on lining…
Read MoreNow that Mynosys Cellular Devices has received FDA 510(k) clearance for its Zepto Capsulotomy System for cataract surgery, the company is planning its US launch…
Read MoreMicroinvasive glaucoma surgery (MIGS) pioneer Reay H. Brown, MD, has long advocated that surgery will be the best treatment option for glaucoma once safety and…
Read MoreAlcon Launches Multifocal Toric IOL at ASCRS Alcon seized the platform of ASCRS 2017 to launch its AcrySof IQ ReSTOR +2.5 multifocal toric intraocular lens…
Read MoreIn October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…
Read MoreWith the recent report of successful top-line Phase III results of its fixed-dose glaucoma candidate Roclatan, Aerie Pharmaceuticals Inc. has seen its stock price soar…
Read MoreSUBSCRIBE TO OIS NEWS
Get Our Weekly Newsletter About The Latest In Ophthalmic Innovation.
We respect your privacy and promise to never send you spam.